Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? - PubMed (original) (raw)
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
R Bilous. Diabet Med. 2008 Aug.
Abstract
The UK Prospective Diabetes Study is the largest study in Type 2 diabetes with pre-specified renal outcomes. The study showed that the natural history of nephropathy in newly diagnosed Type 2 diabetic patients was similar to that described previously in those with Type 1 diabetes. Around 2% per annum progress from normo- to micro-albuminuria [urinary albumin concentration (UAC) > 50 mg/l] and a further 2% from microalbuminuria to clinical grade proteinuria (UAC > 300 mg/l). Mortality rates for those with nephropathy are high, increasing from 1.4% per annum (normoalbuminuria) to 4.6% per annum (clinical grade proteinuria), and to 19.2% per annum for those with renal impairment. More intensive blood glucose control resulted in both a 33% reduction in relative risk of development of microalbuminuria or clinical grade proteinuria at 12 years, and a significant reduction in the proportion doubling their plasma creatinine (0.91 vs. 3.52%, P = 0.0028). Tighter blood pressure control also reduced microalbuminuria and clinical grade proteinuria; but at 6 years there was no effect on plasma creatinine levels. These data underline the importance of glycaemic and blood pressure control in Type 2 diabetes in order to prevent diabetic nephropathy. Those patients unlucky enough to develop nephropathy need intensive surveillance and correction of cardiovascular risk factors.
Similar articles
- Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ, Lewis JB. Lewis EJ, et al. Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review. - Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Adler AI, et al. Kidney Int. 2003 Jan;63(1):225-32. doi: 10.1046/j.1523-1755.2003.00712.x. Kidney Int. 2003. PMID: 12472787 Clinical Trial. - Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
Estacio RO, Jeffers BW, Gifford N, Schrier RW. Estacio RO, et al. Diabetes Care. 2000 Apr;23 Suppl 2:B54-64. Diabetes Care. 2000. PMID: 10860192 Clinical Trial. - Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J; Collaborative Study Group. Lambers Heerspink HJ, et al. Diabet Med. 2007 Nov;24(11):1290-5. doi: 10.1111/j.1464-5491.2007.02249.x. Diabet Med. 2007. PMID: 17956455 Clinical Trial. - [Effect of blood glucose and blood pressure control on progression of diabetic nephropathy].
Schwarz C, Oberbauer R. Schwarz C, et al. Wien Klin Wochenschr. 2000 Nov 10;112(21):907-11. Wien Klin Wochenschr. 2000. PMID: 11144004 Review. German.
Cited by
- Trajectories of Fasting Plasma Glucose and Risks of Chronic Kidney Disease in a General Chinese Population: A Retrospective Study.
Liu J, Ma Y, Yu G, Wang W. Liu J, et al. Int J Gen Med. 2023 Dec 5;16:5695-5702. doi: 10.2147/IJGM.S435451. eCollection 2023. Int J Gen Med. 2023. PMID: 38077477 Free PMC article. - Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus.
Chang LH, Chu CH, Huang CC, Lin LY. Chang LH, et al. Ther Adv Endocrinol Metab. 2023 Oct 29;14:20420188231207345. doi: 10.1177/20420188231207345. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 37916029 Free PMC article. - The long-term benefits of early intensive therapy in chronic diseases-the legacy effect.
Zoccali C, Mallamaci F, Tripepi G, Fu EL, Stel VS, Dekker FW, Jager KJ. Zoccali C, et al. Clin Kidney J. 2023 Aug 10;16(11):1917-1924. doi: 10.1093/ckj/sfad186. eCollection 2023 Nov. Clin Kidney J. 2023. PMID: 37915902 Free PMC article. Review. - Raman Multi-Omic Snapshots of Koshihikari Rice Kernels Reveal Important Molecular Diversities with Potential Benefits in Healthcare.
Pezzotti G, Tsubota Y, Zhu W, Marin E, Masumura T, Kobayashi T, Nakazaki T. Pezzotti G, et al. Foods. 2023 Oct 13;12(20):3771. doi: 10.3390/foods12203771. Foods. 2023. PMID: 37893662 Free PMC article. - SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist.
Granata A, Pesce F, Iacoviello M, Anzaldi M, Amico F, Catalano M, Leonardi G, Gatta C, Costanza G, Corrao S, Gesualdo L. Granata A, et al. Front Nephrol. 2022 Apr 29;2:867075. doi: 10.3389/fneph.2022.867075. eCollection 2022. Front Nephrol. 2022. PMID: 37674992 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical